ALENTIS Therapeutics develops anti-Claudin-1 monoclonal antibodies and antibody-drug conjugates to treat cancer and reverse fibrosis by targeting Claudin-1 to disrupt disease signaling and selectively kill tumor cells. Their clinical pipeline includes candidates for solid tumors and organ fibrosis, addressing significant unmet medical needs in advanced liver disease and various cancers.
Funding
$362.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NHFounders
Product
Problem
Solid tumors and organ fibrosis represent significant unmet medical needs. Current treatments often fail to completely eradicate tumors or reverse fibrosis, leading to disease progression and poor patient outcomes. Existing therapies may also have significant side effects, limiting their long-term use.
Solution
Alentis Therapeutics is developing a pipeline of anti-Claudin-1 monoclonal antibodies and antibody-drug conjugates (ADCs) designed to treat cancer and reverse fibrosis. Their approach targets Claudin-1, a protein exposed on the surface of tumor cells and fibrotic tissue, to disrupt disease signaling and selectively kill tumor cells. By targeting Claudin-1, Alentis aims to open the stiff extracellular matrix, block disease signaling pathways, and deliver cytotoxic payloads directly to cancer cells. This targeted approach has the potential to improve treatment efficacy while minimizing off-target effects.
Target Audience
The primary target audience includes patients with solid tumors, squamous cancers, and organ fibrosis, as well as the physicians who treat these conditions.
Features
- ALE.C04: A monoclonal antibody in clinical development for solid tumors.
- ALE.F02 (Lixudebart): A monoclonal antibody in clinical development for organ fibrosis.
- ALE.P02: An antibody-drug conjugate (ADC) in clinical development for squamous cancers.
- Anti-Claudin-1 ADCs: Preclinical programs focused on developing additional ADCs targeting Claudin-1.
- Bispecific antibodies: Preclinical programs exploring bispecific antibodies that target Claudin-1.
- T-cell engagers: Preclinical programs investigating T-cell engagers that target Claudin-1.